No abstract

No standardized, objective methodology exists for optimizing seeding rates when establishing herbaceous plant cover for pastures, hay fields, ecological restoration, or other revegetation activities. Seeding densities, fertilizer use, season of seeding, and the interaction of these treatments were tested using native plants on degraded sites in northern British Columbia, Canada. A mixture of 20% Achillea millefolium, 20% Carex aenea, 20% Elymus glaucus, 20% Festuca occidentalis, 16% Geum macrophyllum, and 4% Lupinus polyphyllus seed was applied at 0, 375, 750, 1,500, 3,000, and 6,000 pure live seed (PLS) per m 2 in 2.5 3 2.5-m rototilled test plots, established in the fall and spring, with and without fertilizer. There was no significant difference in plant cover of sown species between fall seeding and spring seeding, and few treatment interactions were identified in the first 2 years after sowing. There was no significant difference in cover between seed densities of 3,000 and 6,000 PLS/m 2 in the first year, nor among 1,500, 3,000, and 6,000 PLS/m 2 treatments in the second year. Seed densities as low as 375 PLS/m 2 produced year 2 plant cover equivalent to that observed at 3,000 PLS/m 2 in year 1. Plots sown to seed densities less than or equal to 750 PLS/m 2 generally exhibited an increase (infilling) in plant density from year 1 to year 2, whereas plots sown to seed densities greater than or equal to 1,500 PLS/m 2 generally exhibited a decrease (density-dependent mortality) in plant density. These results imply a most efficient sowing density between 750 and 1,500 PLS/m 2 (corresponding to 190-301 established plants . m 22 after two growing seasons). It is suggested that net changes in plant populations observed over a range of sowing densities are a robust and objective means of determining optimal sowing densities for the establishment of herbaceous perennials.

No abstract

No abstract

The period following heart failure hospitalization (HFH) is a vulnerable time with high rates of death or recurrent HFH.OBJECTIVE To evaluate clinical characteristics, outcomes, and treatment response to vericiguat according to prespecified index event subgroups and time from index HFH in the Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) trial. DESIGN, SETTING, AND PARTICIPANTSAnalysis of an international, randomized, placebo-controlled trial. All VICTORIA patients had recent (<6 months) worsening HF (ejection fraction <45%). Index event subgroups were less than 3 months after HFH (n = 3378), 3 to 6 months after HFH (n = 871), and those requiring outpatient intravenous diuretic therapy only for worsening HF (without HFH) in the previous 3 months (n = 801). Data were analyzed between May 2, 2020, and May 9, 2020.INTERVENTION Vericiguat titrated to 10 mg daily vs placebo. MAIN OUTCOMES AND MEASURESThe primary outcome was time to a composite of HFH or cardiovascular death; secondary outcomes were time to HFH, cardiovascular death, a composite of all-cause mortality or HFH, all-cause death, and total HFH. RESULTS Among 5050 patients in the VICTORIA trial, mean age was 67 years, 24% were women, 64% were White, 22% were Asian, and 5% were Black. Baseline characteristics were balanced between treatment arms within each subgroup. Over a median follow-up of 10.8 months, the primary event rates were 40.9, 29.6, and 23.4 events per 100 patient-years in the HFH at less than 3 months, HFH 3 to 6 months, and outpatient worsening subgroups, respectively. Compared with the outpatient worsening subgroup, the multivariable-adjusted relative risk of the primary outcome was higher in HFH less than 3 months (adjusted hazard ratio, 1.48; 95% CI, 1.27-1.73), with a time-dependent gradient of risk demonstrating that patients closest to their index HFH had the highest risk. Vericiguat was associated with reduced risk of the primary outcome overall and in all subgroups, without evidence of treatment heterogeneity. Similar results were evident for all-cause death and HFH. Addtionally, a continuous association between time from HFH and vericiguat treatment showed a trend toward greater benefit with longer duration since HFH. Safety events (symptomatic hypotension and syncope) were infrequent in all subgroups, with no difference between treatment arms.CONCLUSIONS AND RELEVANCE Among patients with worsening chronic HF, those in closest proximity to their index HFH had the highest risk of cardiovascular death or HFH, irrespective of age or clinical risk factors. The benefit of vericiguat did not differ significantly across the spectrum of risk in worsening HF.